Narsoplimab
Generic Name: narsoplimab
Brand Names:
Yartemlea
11 DESCRIPTION Narsoplimab-wuug, a mannan-binding lectin-associated serine protease 2 (MASP-2) inhibitor, is a recombinant human immunoglobulin G4 (IgG4) monoclonal antibody produced in Chinese Hamster Ovary cells. The approximate molecular weight is 143 kDa. YARTEMLEA (narsoplimab-wuug) injection is a sterile, preservative-free, clear to slightly opalescent, slightly yellow to yellow-brown solution for intravenous infusion.
Overview
11 DESCRIPTION Narsoplimab-wuug, a mannan-binding lectin-associated serine protease 2 (MASP-2) inhibitor, is a recombinant human immunoglobulin G4 (IgG4) monoclonal antibody produced in Chinese Hamster Ovary cells. The approximate molecular weight is 143 kDa. YARTEMLEA (narsoplimab-wuug) injection is a sterile, preservative-free, clear to slightly opalescent, slightly yellow to yellow-brown solution for intravenous infusion.
Uses
1 INDICATIONS AND USAGE YARTEMLEA is indicated for the treatment of adult and pediatric patients 2 years of age and older with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). YARTEMLEA is a MASP-2 inhibitor indicated for the treatment of adult and pediatric patients 2 years of age and older with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). ( 1 )
Dosage
2 DOSAGE AND ADMINISTRATION Weight (kg) Recommended Dosage Greater than or equal to 50 kg 370 mg given as an intravenous infusion over 30 minutes once weekly. Increase frequency to twice weekly if there is inadequate improvement in TA-TMA signs and symptoms. ( 2.1 ) Less than 50 kg 4 mg/kg given as an intravenous infusion over 30 minutes once weekly. Increase frequency to twice weekly if there is inadequate improvement in TA-TMA signs and symptoms. ( 2.1 ) See Full Prescribing Information for instructions on preparation and administration. ( 2.2 , 2.3 , 2.4 , 2.5 ) 2.1 Recommended Dosage The recommended dosage of YARTEMLEA is provided in Table 1 .
Side Effects
6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: Serious Infections [see Warnings and Precautions ( 5.1 )] Most common adverse reactions (incidence > 20% and independent of causality) are viral infections, sepsis, hemorrhage, diarrhea, vomiting, nausea, neutropenia, pyrexia, fatigue and hypokalemia. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Omeros Corporation at 1-844-YARTEM1 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .
Warnings
5 WARNINGS AND PRECAUTIONS Serious infections: Monitor patients for signs/symptoms and treat appropriately. ( 5.1 ) 5.1 Serious Infections Serious and life-threatening infections have occurred in patients treated with YARTEMLEA. Serious infections, independent of causality, were reported in 36% (10/28) of patients with TA-TMA receiving YARTEMLEA in clinical trials. These infections included sepsis, viral infections, pneumonia, bacteremia, fungal infection, gastroenteritis, respiratory tract infection and urosepsis. If YARTEMLEA is administered to patients with active infections, monitor closely for signs and symptoms of worsening infection and treat promptly. 4 CONTRAINDICATIONS None None ( 4 )
Pregnancy
8.1 Pregnancy Risk Summary The available data on the use of YARTEMLEA during pregnancy are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. In animal reproduction studies, narsoplimab-wuug was administered subcutaneously and intravenously twice weekly to pregnant mice and rabbits during organogenesis at dose exposures up to 22 and 91-fold, respectively, the human exposure at the maximum recommended human dose (MRHD) based on area under the concentration-time curve (AUC).
Storage
16 HOW SUPPLIED/STORAGE AND HANDLING YARTEMLEA (narsoplimab-wuug) injection is a sterile, preservative-free, clear to slightly opalescent, slightly yellow to yellow-brown solution supplied as one 370 mg/2 mL (185 mg/mL) single-dose vial in a carton (NDC 62225-300-00). Store YARTEMLEA vials refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light until time of use.
Frequently Asked Questions
What is Narsoplimab used for?▼
1 INDICATIONS AND USAGE YARTEMLEA is indicated for the treatment of adult and pediatric patients 2 years of age and older with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). YARTEMLEA is a MASP-2 inhibitor indicated for the treatment of adult and pediatric patients 2 years of age and older with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). ( 1 )
What are the side effects of Narsoplimab?▼
6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: Serious Infections [see Warnings and Precautions ( 5.1 )] Most common adverse reactions (incidence > 20% and independent of causality) are viral infections, sepsis, hemorrhage, diarrhea, vomiting, nausea, neutropenia, pyrexia, fatigue and hypokalemia. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Omeros Corporation at 1-844-YARTEM1 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .
Can I take Narsoplimab during pregnancy?▼
8.1 Pregnancy Risk Summary The available data on the use of YARTEMLEA during pregnancy are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. In animal reproduction studies, narsoplimab-wuug was administered subcutaneously and intravenously twice weekly to pregnant mice and rabbits during organogenesis at dose exposures up to 22 and 91-fold, respectively, the human exposure at the maximum recommended human dose (MRHD) based on area under the concentration-time curve (AUC).
What are the important warnings for Narsoplimab?▼
5 WARNINGS AND PRECAUTIONS Serious infections: Monitor patients for signs/symptoms and treat appropriately. ( 5.1 ) 5.1 Serious Infections Serious and life-threatening infections have occurred in patients treated with YARTEMLEA. Serious infections, independent of causality, were reported in 36% (10/28) of patients with TA-TMA receiving YARTEMLEA in clinical trials. These infections included sepsis, viral infections, pneumonia, bacteremia, fungal infection, gastroenteritis, respiratory tract infection and urosepsis. If YARTEMLEA is administered to patients with active infections, monitor closely for signs and symptoms of worsening infection and treat promptly. 4 CONTRAINDICATIONS None None ( 4 )
Related Medications
Agnus Castus, Aralia Quinquefolia, Lycopodium Clavatum, Petroselinum Sativum, Sabal Serrulata, Urtica Dioica, Xanthoxylum Fraxineum, Pulsatilla (vulgaris), Glandula Suprarenalis Suis, Hypophysis Suis, Orchitinum (suis), Prostate (suis), Clematis Erecta, Juniperus Virginiana
agnus castus, aralia quinquefolia, lycopodium clavatum, petroselinum sativum, sabal serrulata, urtica dioica, xanthoxylum fraxineum, pulsatilla (vulgaris), glandula suprarenalis suis, hypophysis suis, orchitinum (suis), prostate (suis), clematis erecta, juniperus virginiana
INDICATIONS: For temporary relief of lowered vitality with depressed feelings, loss of nervous energy and pressure in the testicles.
Araneus Diadematus, Tribasic Calcium Phosphate,equisetum Hyemale Whole, Ferrous Iodide,fumaria Officinalis Flowering Top, Gentiana Lutea Root, Juglans Regia Leaf, Levothyroxine Sodium Anhydrous, Myosotis Arvensis Whole,nasturtium Officinale,sodium Sulfate, Pinus Sylvestris Leafy Twig,smilax Ornata Root,scrophularia Nodosa Whole, Teucrium Scorodonia Flowering, Veronica Officinalis Flowering Top
araneus diadematus, tribasic calcium phosphate,equisetum hyemale whole, ferrous iodide,fumaria officinalis flowering top, gentiana lutea root, juglans regia leaf, levothyroxine sodium anhydrous, myosotis arvensis whole,nasturtium officinale,sodium sulfate, pinus sylvestris leafy twig,smilax ornata root,scrophularia nodosa whole, teucrium scorodonia flowering, veronica officinalis flowering top
Dosage form: TABLET. Active ingredients: ARANEUS DIADEMATUS (6 [hp_X]/1); EQUISETUM HYEMALE WHOLE (4 [hp_X]/1); FERROUS IODIDE (12 [hp_X]/1); FUMARIA OFFICINALIS FLOWERING TOP (4 [hp_X]/1); GENTIANA LUTEA ROOT (5 [hp_X]/1); GERANIUM ROBERTIANUM (4 [hp_X]/1); JUGLANS REGIA LEAF (3 [hp_X]/1); LEVOTHYROXINE SODIUM ANHYDROUS (12 [hp_X]/1); MYOSOTIS ARVENSIS WHOLE (3 [hp_X]/1); NASTURTIUM OFFICINALE (4 [hp_X]/1); PINUS SYLVESTRIS LEAFY TWIG (4 [hp_X]/1); SCROPHULARIA NODOSA WHOLE (3 [hp_X]/1); SMILAX
Enoxacin
enoxacin
Manufactured by SANOFI AVENTIS US. Dosage form: TABLET. Route: ORAL. Active ingredients: ENOXACIN (200MG). Application: NDA019616.
Medical Disclaimer
This drug information is for educational purposes only and should not replace professional medical advice. Drug information is sourced from the FDA National Drug Code Directory and Structured Product Labeling. Always consult with a healthcare provider before starting, stopping, or changing any medication.